Objective Asthma is one of the prevalent diseases in children. There is some evidence regarding the benefits of camel milk in asthma. The present study was carried out to evaluate the effect of camel milk on asthmatic children. Patients and Methods A randomized double‐blind pilot study was operated in 2018 in a tertiary center. Sixty children aged more than 6 years with not well‐controlled asthma were included. The intervention was consisting of 200‐ml camel milk or placebo daily for 2 months. The medication regimen and spirometry parameters were assessed before and after the intervention. Data were analyzed using SPSS software. Results A total of 57 patients completed the trial. Patients were similar in demographic and baseline characteristics (p > 0.05). There was a significant difference between groups after intervention in use of inhaled corticosteroids (96.7% vs. 70.4%, p value = 0.01), short‐acting beta‐agonists (53.3% vs. 29.6%, p value = 0.0001) and long‐acting beta‐agonists (53.3% vs. 40.7%, p value = 0.04) in control and intervention, respectively. The percent of changes in forced expiratory volume (FEV1) in the control and intervention groups was 18.54 ± 14.89 and 21.89 ± 17.83, respectively (p = 0.19). The percent of changes in FEV1/forced vital capacity (FVC) in the control and intervention groups was 8.11 ± 7.12 and 11.11 ± 8.33, respectively (p = 0.14). Conclusion In our pilot study, some children with asthma may benefit from camel milk. Further studies would be useful to evaluate this hypothesis.

Asthma is one of the prevalent diseases in children. There is some evidence regarding benefits of camel milk in asthma. Present study was carried out evaluating the effect of camel milk in asthmatic children. A randomized double blind clinical trial was operated between 2018 and 2019 in a tertiary center. Sixty children aged more than 6 years with not well control asthma were included. Intervention was consist of 200 milliliter camel milk or placebo daily for 2 months. Spirometry parameters and medication regimen were assessed before and after intervention. Data was analyzed using SPSS software. A total of 57 patients completed the trial. Patients were similar in demographic and baseline characteristics (p > 0.05). There was a significant difference between groups after intervention in use of inhaled corticosteroids (96.7% versus 70.4%, p value = 0.01), short acting beta agonists (53.3% versus 29.6%, p value = 0.0001) and long acting beta agonists (53.3% versus 40.7%, p value = 0.04) in control and intervention respectively. The percent of changes in forced expiratory volume (FEV1) in control and intervention groups was 18.54 ± 14.89 and 21.89 ± 17.83 respectively (p = 0.14). The percent of changes in FEV1/forced vital capacity (FVC) in control and intervention groups was 8.11 ± 7.12 and 11.11 ± 8.33 respectively (p = 0.14). Conclusion: Camel milk leads to significant decrease in inhaled corticosteroids, short acting beta agonists and long acting beta agonist's use, surprisingly. It was suggested that camel milk is added to pharmacological treatment of asthmatic children after more studies.